Data. by Michael C. Payne (2664379)

Subjects:

Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

Tumor volume measurements. by Hedieh Zargaran (21410233)

Prescription data. by Dainty Ei (22265317)

Subjects:

IL-10 levels in tumor lysates post-treatment. by Hedieh Zargaran (21410233)

Comparison of absolute and relative errors. by Lahoucine Tadoummant (21647670)

Subjects:

Rate of convergence for relative errors. by Lahoucine Tadoummant (21647670)

Subjects:

Ultrafine Particulate Matter Exacerbates the Risk of Delayed Neural Differentiation: Modulation Role of METTL3-Mediated m⁶A Modification by Rui Wang (52434)

Subjects:

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…</p>Objective<p>This study aims to elucidate the clinical implications of concurrent AICDA and IKBKB homozygous variants in a pediatric patient diagnosed with hyper-IgM syndrome.</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”

Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

Subjects:

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

S1 Graphical - by Agnieszka Murawska (11021928)

Subjects:

Col outcomes QR. by Felipe Agudelo-Hernández (20790521)

“…</p><p>Results</p><p>Statistically significant improvements were observed in human rights understanding, reduced stigmatizing attitudes toward mental health and decreased authoritarianism. …”

Pre-post comparison of study variables. by Felipe Agudelo-Hernández (20790521)

“…</p><p>Results</p><p>Statistically significant improvements were observed in human rights understanding, reduced stigmatizing attitudes toward mental health and decreased authoritarianism. …”

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …”